Technical analysis of NewAmsterdam Pharma Company N.V. (NAMS): price and volume charts, candlestick patterns, moving averages (SMA, EMA), RSI, MACD, ADX and Bollinger Bands. Identify momentum, trend direction and potential entry/exit zones.
NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with cardiometabolic disease. It is developing Obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.
Price Performance
| 1 month | -22.28% |
| 3 months | -29.00% |
| Year-to-date | -39.62% |
| 1 year | -13.52% |
| 3 years | +115.68% |
| 5 years | +115.90% |
52-Week Range
| 52-week High | $42.21 |
| 52-week Low | $21.02 |
| Avg Volume (90d) | 1.3M |
Technical Indicators
| SMA 50 | $27.94 |
| SMA 200 | $31.98 |
| Beta | 0.13 |
| 30-day Volatility (annualised) | 49.5% |
| Price vs SMA 50 | -24.2% |
| Price vs SMA 200 | -33.8% |
Monthly Close (12 months)
| Month | Close | Change |
|---|
| 2025-10 | $37.95 | |
| 2025-11 | $41.30 | +8.8% |
| 2025-12 | $35.08 | -15.1% |
| 2026-01 | $31.12 | -11.3% |
| 2026-02 | $35.46 | +13.9% |
| 2026-03 | $32.01 | -9.7% |
| 2026-04 | $28.56 | -10.8% |
| 2026-05 | $33.68 | +17.9% |
| 2026-06 | $33.89 | +0.6% |
| 2026-07 | $27.79 | -18.0% |
| 2026-08 | $25.34 | -8.8% |
| 2026-09 | $21.18 | -16.4% |
Upcoming Earnings
| Date | EPS Est. | Revenue Est. |
|---|
| 2026-09-14 | | |
| 2026-09-14 | $-0.06 | |
| 2026-09-14 | $0.03 | $3M |
| 2026-09-14 | | |
| 2026-09-14 | $-0.06 | $36M |
| 2026-09-14 | $0.84 | $26M |
Price
| Price | $21.18 |
| Market Cap | $2.5B |
| Exchange | NASDAQ |
| Country | NL |
Valuation Ratios
| Price / Book | 5.45 |
| EV / EBITDA | -14.54 |
| Dividend Yield | 0.00% |
Financial Health
| Debt / Equity | 0.00 |
| Current Ratio | 7.88 |